Profile data is unavailable for this security.
About the company
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.
- Revenue in USD (TTM)0.00
- Net income in USD-120.74m
- Incorporated2011
- Employees70.00
- LocationAnnexon Inc1400 SIERRA POINT PARKWAYBLDG C SUITE 200BRISBANE 94005United StatesUSA
- Phone+1 (650) 822-5500
- Fax+1 (650) 636-9773
- Websitehttps://annexonbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | -477.00k | -193.56m | 581.62m | 26.00 | -- | 8.64 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| iTeos Therapeutics Inc | 0.00 | -135.31m | 596.21m | 157.00 | -- | 1.09 | -- | -- | -3.78 | -3.78 | 0.00 | 15.10 | 0.00 | -- | -- | 0.00 | -19.93 | 5.84 | -20.88 | 7.02 | -- | -- | -- | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Allogene Therapeutics Inc | 87.00k | -292.30m | 602.23m | 232.00 | -- | 1.07 | -- | 6,922.18 | -1.78 | -1.78 | 0.0005 | 2.71 | 0.0001 | -- | -- | 375.00 | -43.85 | -28.46 | -47.04 | -30.21 | -- | -- | -335,973.60 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Annexon Inc | 0.00 | -120.74m | 602.79m | 70.00 | -- | 2.01 | -- | -- | -1.46 | -1.46 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -42.15 | -44.06 | -44.99 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| Verve Therapeutics Inc | 16.05m | -196.83m | 602.87m | 255.00 | -- | 1.03 | -- | 37.56 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Ginkgo Bioworks Holdings Inc | 208.70m | -853.81m | 603.21m | 1.22k | -- | 0.5893 | -- | 2.89 | -0.4347 | -0.4347 | 0.1061 | 0.4855 | 0.1044 | -- | 3.82 | 171,344.00 | -42.70 | -- | -46.94 | -- | 80.43 | -- | -409.12 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 603.57m | 42.00 | -- | 2.61 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| ProKidney Corp | 0.00 | -35.30m | 605.88m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 608.53m | 216.00 | -- | 3.77 | -- | 289.09 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 613.05m | 709.00 | -- | 2.23 | -- | 3.51 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.3238 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Alector Inc | 96.41m | -120.61m | 613.97m | 244.00 | -- | 3.43 | -- | 6.37 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 615.53m | 29.00 | -- | 7.06 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -125.32m | 618.82m | 57.00 | -- | 3.13 | -- | -- | -2.94 | -2.94 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -58.14 | -- | -73.35 | -- | -- | -- | -- | -- | -- | -- | 0.0675 | -- | -- | -- | -68.55 | -- | -- | -- |
| GH Research PLC | 0.00 | -35.59m | 621.74m | 49.00 | -- | 2.84 | -- | -- | -0.6841 | -0.6841 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -14.81 | -- | -15.16 | -- | -- | -- | -- | -- | -- | -- | 0.0044 | -- | -- | -- | -58.47 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 622.93m | 19.00 | -- | 6.32 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to Annexon Inc's reporting currency: US Dollar USD
44.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.37m | 8.89% |
| BVF Partners LPas of 31 Mar 2024 | 7.00m | 6.64% |
| Redmile Group LLCas of 31 Mar 2024 | 5.50m | 5.22% |
| Point72 Asset Management LPas of 31 Mar 2024 | 5.16m | 4.89% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 4.42m | 4.20% |
| Adage Capital Management LPas of 31 Mar 2024 | 4.32m | 4.10% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.68m | 3.50% |
| Logos Global Management LPas of 31 Mar 2024 | 3.05m | 2.89% |
| GMT Capital Corp.as of 31 Mar 2024 | 2.65m | 2.51% |
| Bellevue Asset Management AGas of 31 Mar 2024 | 2.18m | 2.07% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
